DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Danaher - 3 Beckman Coulter - 3 Jim Cramer's - 3 Jim Cramer - 3 Jim - 3 Blair - 2 Igor Golovnov - 2 Sartorius - 1
Top related locs:
Europe China bioprocessing Danaher North America U.S Bioprocessing Biotechnology
Top related orgs:
LSEG - 3 Management - 3 CNBC - 3 Getty - 3 Revenue - 2 Diagnostics - 2 Beckman Coulter Diagnostics - 2 Biotechnology - 2

Search resuls for: "Beckman Coulter"


3 mentions found


☆ We're raising our price target on Danaher stock as it sheds a major overhang
  + stars: | 2024-07-23 | by ( Zev Fima | ) www.cnbc.com   time to read: +10 min
That improvement in the bioprocessing end market is super important because it has been a huge overhang for Danaher shares, and the life sciences space in general. We were concerned about the bioprocessing market after rival Sartorius cut its guidance last week. The management team has effectively navigated the bioprocessing slowdown better than others and kept expectations managed — a big reason we've stuck by the stock during a difficult few quarters. Based on these strong results and the improving bioprocessing market, we are raising our price target to $295 from $280 and reiterating our 1 rating. All three operating segments are expected to post sales decline rates in the low single digits.
Persons: Sartorius, Rainer Blair, Danaher, Blair, Beckman Coulter, Jim Cramer's, Jim Cramer, Jim, Igor Golovnov Organizations: Club, Revenue, LSEG, Management, Diagnostics, Leica, Beckman Coulter Diagnostics, Cepheid, CNBC, Getty Locations: bioprocessing, Danaher, U.S, Europe, China, Bioprocessing
☆ Danaher shares jump 7% as the turnaround in biotech spending finally arrives
  + stars: | 2024-04-23 | by ( Zev Fima | ) www.cnbc.com   time to read: +8 min
Shares of Danaher popped more than 7% on Tuesday after the life sciences company delivered beats across its three main businesses — a sign the long-awaited turnaround in the biotech industry is finally here. Danaher Why we own it : Danaher is a best-in-class life sciences and diagnostics company, with a management team who have proven time and again their ability to find new ways to grow. The turnaround is now in effect, with bioprocessing orders up on a sequential basis. Within the segment, bioprocessing sales fell a "high teens" percentage, while discovery and medical declined 20% year over year. Diagnostics sales advanced 7.5% on a core basis to $2.53 billion.
Persons: Danaher, Blair, Beckman Coulter, Jim Cramer's, Jim Cramer, Jim, Igor Golovnov Organizations: LSEG, Bloomberg, Biotechnology, Management, CNBC, Getty Locations: bioprocessing, China, North America, Europe
☆ Danaher shares hit a 1-year high after earnings and we're increasing our price target
  + stars: | 2024-01-30 | by ( Zev Fima | ) www.cnbc.com   time to read: +10 min
DHR 1Y mountain Danaher 1 year Shares of Danaher rose as much as 5% to a 52-week high of $245.40 each. Core sales, not shown on the table, were down 22.5%. Core sales were down 4% year over year as strength from academic and life science research customers was more than offset by weakness from pharma and biopharma customers. Core sales fell about the same as strength in clinical diagnostics, driven by Beckman Coulter Diagnostics was more than offset by lower respiratory revenue at Cepheid. In this photo illustration, Danaher Corporation logo is seen displayed on a smartphone and PC screen.
Persons: we've, Danaher, Beckman Coulter, Jim Cramer's, Jim Cramer, Jim, Pavlo Gonchar Organizations: Revenue, LSEG, JPMorgan Healthcare, Sciences, Diagnostics, Biotechnology, Management, pharma, Beckman Coulter Diagnostics, CNBC, Getty Locations: Danaher, China, Biotechnology, North America, Europe, Asia, Pacific, Cepheid
0 next >>
Total: 3